Hard to Treat Diseases (HTDS) Releases experimental results in the treatment of (MS) Multiple...( BELGRADE March 16 / Hard to Treat Dis...),Health

BELGRADE, March 16 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com is pleased to announce that a group of investigators (lead by Professor Mirjana Stojiljkovic) from Department of Neurobiology, Institute for Biological Research "Sinisa Stankovic", University of Belgrade, Serbia, (IBISS group) introduced a novel therapeutic approach in treatment of multiple sclerosis (MS), a severe, currently incurable, human disease. The effectiveness of this therapy is shown in experimental animals and has to be proven in people with MS, so that obtained results has to be considered as "experimental." Experimental data obtained on laboratory animals provide the following beneficial effects of the therapy:

    -   The severity of clinical signs of disease was significantly reduced
    -   The pathological changes in the myelin sheath (demyelination) were
        not detected
    -   The reduction of mononuclear cell infiltrates, composed of T cells
        and macrophages/microglia was observed in the spinal cord tissue
    -   The degree of disability was lowered
    -   The duration of the disease was notably shortened
    -   The percentage mortality in severe disease was radically reduced
        (70%)
    -   The severity of treatment side effects was low and disappeared after
        cessation of drug application

In 2005 IBISS group received a prestige reward - The first place and golden medal of Nikola Tesla at the International Festival of Innovations, Know-how and Creativity. The award can be viewed at the company's corporate web site www.htdsmedical.com

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain forward information contained in this release contains forward-looking statements that involve risk and uncertainties, inclu
'/>"/>